CYP2J2 ∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients

Chemotherapy induced hematologic toxicity is the primary reasons of dose reductions and/or delays, low relative dose intensity (RDI), and predicts anticancer response. We investigated the incidence and predictors of chemotherapy-induced hematologic toxicities and reduced RDI in Ethiopian breast cancer patients, and the implication of genetic variations. Breast cancer patients (n=249) were enrolled prospectively to receive cyclophosphamide based chemotherapy. Hematological toxicity were monitored throughout chemotherapy cycle. The primary and secondary outcomes were incidence of grade 3 or 4 hematologic toxicity and reduced RDI, respectively. CYP2B6*6, CYP3A5*3, CYP2C9 (*2,*3), CYP2C19 (*2,*3), CYP2J2*7, and POR*28 genotyping were done. Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively. Majority (73.5%) of the patients were
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research